Literature DB >> 16258022

DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.

Ching-Chuan Kuo1, Jin-Fen Liu, Jang-Yang Chang.   

Abstract

Two camptothecin-resistant cell lines, CPT30 and KB100, were established and characterized previously in our laboratory. Because enhanced sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and decreased expression of O(6)-methylguanine-DNA methyltransferase (MGMT) protein were observed in these lines, we hypothesized that MGMT may be a determinant of cytotoxicity associated with camptothecin-derived DNA topoisomerase I inhibitors (CPTs). We used the Tet-On system to induce expression of MGMT in Chinese hamster ovary (CHO) cells and RNA interference to knock down MGMT expression in human nasopharyngeal carcinoma HONE-1 cells in order to identify any correlations between MGMT expression and CPTs cytotoxicity. CHO-derived Tet-On-inducible cells (S12+) showed MGMT overexpression and statistically significant more resistance to BCNU, camptothecin, 7-ethyl-10-hydrocamptothecin (SN38), and topotecan than parental CHO cells (p < 0.05), but there was less resistance to CPTs than to BCNU. Knockdown of MGMT expression with small interfering RNA in HONE-1 cells conferred increased sensitivity to BCNU and CPTs compared with mock control. Furthermore, alteration of MGMT expression coincides with CPT-induced cell death and poly(ADP-ribose) polymerase cleavage. There were no differences in protein levels and catalytic activity of topoisomerase I between MGMT-proficient and MGMT-deficient cells from the Tet-On-inducible and small interfering RNA (siRNA) systems. Resistance to CPTs coincided with decreased amounts of protein-linked DNA breaks generated by CPTs in MGMT-proficient cells and vice versa in MGMT-deficient cells. Our data indicate that MGMT can modulate cytotoxicity of CPT-derived topoisomerase I inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258022     DOI: 10.1124/jpet.105.095919

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX.

Authors:  Carole Vitellius; Caroline Eymerit-Morin; Dominique Luet; Lionel Fizanne; Fanny Foubert; Sandrine Bertrais; Marie-Christine Rousselet; François-Xavier Caroli-Bosc
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

2.  Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells.

Authors:  David Davidson; Jeremy Grenier; Veronica Martinez-Marignac; Lilian Amrein; May Shawi; Marc Tokars; Raquel Aloyz; Lawrence Panasci
Journal:  Invest New Drugs       Date:  2011-05-13       Impact factor: 3.850

3.  Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

Authors:  David Davidson; Yannick Coulombe; Veronica L Martinez-Marignac; Lilian Amrein; Jeremy Grenier; Keira Hodkinson; Jean-Yves Masson; Raquel Aloyz; Lawrence Panasci
Journal:  Invest New Drugs       Date:  2011-01-11       Impact factor: 3.850

4.  Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells.

Authors:  Müge Sak; Cory T Zumbar; Paul D King; Xiaohui Li; Caroline S Mifsud; Aisulu Usubalieva; Charles D Anderson; Hailey M Chesnick; Joseph P McElroy; Arnab Chakravarti; Eric C Burton; Norman L Lehman
Journal:  J Neurooncol       Date:  2019-04-22       Impact factor: 4.130

Review 5.  Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.

Authors:  Guan Jiang; Ai-Jun Jiang; Yong Xin; Lian-Tao Li; Qian Cheng; Jun-Nian Zheng
Journal:  Mol Biol Rep       Date:  2014-07-03       Impact factor: 2.316

6.  Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.

Authors:  Thomas Viel; Parisa Monfared; Sonja Schelhaas; Inga B Fricke; Michael T Kuhlmann; Cornel Fraefel; Andreas H Jacobs
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

7.  Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; Henry S Friedman
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

8.  MGMT in colorectal cancer: a promising component of personalized treatment.

Authors:  Le Zhang; Jing Zeng; Zhaolei Zeng; Fenghua Wang; Deshen Wang; Cui Chen; Cong Li; Xin An; Ruihua Xu; Peng Huang; Yi Ba; Yuhong Li
Journal:  Tumour Biol       Date:  2016-03-22

9.  DNA-Binding and Topoisomerase-I-Suppressing Activities of Novel Vanadium Compound Van-7.

Authors:  Xiao-Mei Mo; Zhan-Fang Chen; Xin Qi; Yan-Tuan Li; Jing Li
Journal:  Bioinorg Chem Appl       Date:  2012-09-30       Impact factor: 7.778

10.  Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond.

Authors:  David Davidson; Lilian Amrein; Lawrence Panasci; Raquel Aloyz
Journal:  Front Pharmacol       Date:  2013-01-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.